Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Multicenter phase 1-2 MonumenTAL-1 study of talquetamab in relapsed/refractory myeloma -> ORR 74% in 0.4 mg/kg weekly group, 69% in 0.8 mg/kg q2 wks, 67% in previous TCR group; common AEs = CRS, taste changes and infections.”

“Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1–2 study”

Authors: Ajai Chari, Cyrille Touzeau, Carolina Schinke, Monique Minnema, Jesus Berdeja, Jenna Goldberg, Colleen Kane, Christoph Heuck, Jesus San-Miguel, Philippe Moreau et al.

Myeloma Paper of the Day, March 18th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.